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Abstract
Rapid and accurate diagnosis of heart attacks—and the assessment of damage—are critical for
improving coronary care. Mature microRNAs (miRNAs) are abundant, easily measured, and relatively
stable in blood plasma. If they prove indicative of disease states, miRNAs measured from peripheral
blood may be a particularly attractive source for routine clinical assessments.
Introduction
MicroRNAs (miRNAs) were discovered almost twenty
years ago, but during the past 5 years, research has
exploded in this field (e.g., approximately 9,000 manu-
scripts have been published since 2006) (see miRNA
reviews [1,2]). The major reason for this flood of interest
has resulted from the demonstration that mature miRNAs
(i.e., single-stranded RNA molecules comprising 21–23
nucleotides in length)can play a critical roleinthe control
of most biological processes, including cell differentiation
andproliferation,migration,development,andapoptosis.
Importantly, recent investigations have established that
aberrantregulation ofmaturemiRNAexpressionisclosely
associated with the onset and progression of many
diseases, including cardiovascular disease. It is now clear
thatepigenetic modifications such as DNA methylationor
histone acetylation can affect miRNA expression, and
potentially be responsible for the aberrant miRNA
regulation observed in cardiovascular disease. Moreover,
a specific group of miRNAs defined as epigenetic miRNAs
can directly target effectors of the epigenetic machinery
and indirectly affect the expression of genes involved in
cardiovascular disease. Given that the dysregulation of
miRNA expression appears to play a significant role in
mediating the pathology of diseased hearts, miRNAs may
represent unique diagnostic and therapeutic targets.
miRNAs as diagnostic tools for cardiovascular
disease
The ideal biomarker for any disease must be accessible
using noninvasive techniques, economical to quantify,
specific to the disease of interest, and a reliable early
indicator of disease before clinical symptoms appear.
Given that mature miRNAs are abundant, easily
measurable, and relatively stable in the plasma/
serum, peripheral blood may be a particularly attrac-
tive source for the routine clinical measurement of
these molecules in disease settings [3]. In support of
this premise, several independent studies have demon-
strated that, in plasma samples isolated from patients
with acute myocardial infarction, cardiac myocyte-
associated mature miR-208b and -499 were greatly
elevated when compared with controls [4,5]. Another
study demonstrated that mature miR-1 levels were
significantly higher in plasma from acute myocardial
infarction patients compared with subjects without
acute myocardial infarction, and the level returned to
normal upon discharge following medication [6].
Importantly, these investigators also established that
plasma mature miRNA levels were not affected by a
wide range of clinical confounders, including age,
gender, body mass index, kidney function, systolic
blood pressure, and white blood cell count. Taken
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myocardial infarction, mature miR-1, -208, and -499
are released into the plasma as a result of damaged
cardiac cells and may therefore be useful biomarkers in
myocardial infarction patients to evaluate the efficacy
of treatment or for risk stratification in patients with
chronic coronary artery disease.
Although it appears that mature plasma miRNAs may
be useful indicators of myocardial injury, can plasma
miRNA signatures also be utilized to diagnose other
forms of cardiovascular disease? To begin to address
this question, Tijsen et al. [7] assayed mature plasma
miRNAs isolated from 12 healthy controls and
12 stable, chronic heart failure patients. These investi-
gators excluded subjects with recent cardiac ischemia or
infarction, so their results were less likely to be
influenced by major cardiac cell loss. Importantly,
they did not find increased mature miR-1, -208, or -499
in the plasma of heart failure patients. However, they
did identify six miRNAs that were elevated in the
plasma of patients with heart failure, among which
mature miR-423-5p was the most strongly related to
the clinical diagnosis of heart failure. While miR-423-
5p may be an attractive novel plasma miRNA biomar-
ker specific for heart failure, several important
questions remain unanswered. What cell type(s)
produce miR-423-5p? Do increased levels of plasma
mature miR-423-5p reflect the existence of a specific
miRNA secretory/shedding pathway or does the miRNA
release result from cell death and subsequent emptying
of cellular contents into the extracellular space?
Interestingly, it has been suggested that extracellular
mature miRNAs in plasma and other body fluid types
may participate in some form of cell-to-cell communica-
tion. It is further speculated that these mature miRNAs
convey specific information, and therefore only some
cellular mature miRNAs would be exported or released
from cells in response to biological stimuli [8]. However,
others have argued that these molecules are not
biologically active given that it is unlikely that these
secreted mature miRNAs can be incorporated into
miRNA-induced ribonucleoprotein silencing complexes
(RISCs) in target cells [9]. It will be extremely intriguing
to monitor how this controversy is resolved, and what
the implications will be for miRNAs in this setting.
miRNAs and cardiac regeneration
Three manifestations of heart disease—cardiac hypertro-
phy, heart failure, and myocardial infarction—are each
associated with distinct miRNA expression patterns. In
instances where attenuation of a particular miRNA
appears pathogenic, therapeutically increasing miRNA
levels could be beneficial. Myocardial regeneration
provides one of the most appealing therapeutic options
to restore myocardial function to an injured or diseased
heart, and there is some evidence that miRNAs could
facilitate the process.
Mesenchymal stem cells derived from adult bone
marrow have emerged as one of the most promising
stem cell types for treating cardiovascular disease [10]. In
a fascinating study, Lai et al. [11] demonstrated that
mesenchymal stem cells shed/secreted phospholipid
Table 1. miRNA nomenclature as adopted by the miRNA Registry [20]
miRNA Nomenclature Example
miRNA The prefix “mir” is followed by a dash and a number, mir-123 was likely discovered
before mir-423
Pre-miRNA Indicated by the uncapitalized prefix “mir” mir-155
Mature form of miRNA Indicated by the capitalized prefix “miR” miR-155
miRNAs with nearly identical sequences
(i.e., one or two nucleotides different)
Denoted with an additional lowercase letter miR-125a
miR-125b
Pre-miRNAs that are located at distinct genomic loci
but that lead to identical mature miRNA
Denoted with an additional dash-number suffix mir-125b-1
mir-125b-2
Two mature miRNAs that have originated from
opposite arms of the same pre-miRNA, when
relative expression levels are known
The predominant miRNA is named as described
above and the other miRNA expressed at lower
levels is followed by an asterisk
miR-155
miR-155*
When the relative expression levels of the two mature
miRNAs originating from opposite arms of the same
pre-miRNA are not known
The suffix -5p is added to the miRNA originating
from the 5
0 arm, and -3p is added to the miRNA
from the 3
0 arm
miR-423-5p
miR-423-3p
miRNA that originates from different species The species of origin is designated by a three-letter
prefix
hsa-miR-155 (Homo sapiens)
mmu-miR-155 (Mus musculus)
Before receiving a number designation, the guidelines require that the new miRNA gene is experimentally verified by cloning or with evidence of
expression and processing.
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which is attributed sequentiallya
avesicles consisting of cholesterol, sphingomyelin, and
phosphatidylcholine and that these purified particles
reduced tissue damage in a mouse model of myocardial
ischemia/reperfusion injury. Additionally, this labora-
tory also demonstrated that mesenchymal stem cells
shed/secreted phospholipid vesicles that were enriched
with pre-miRNAs (i.e., ~70-nucleotide hairpin structures
that are incorporated into the RISC where they are
cleaved by Dicer to give rise to mature functional
miRNAs), which, unlike single-stranded, mature
miRNA, can be readily taken up by other cell types [9].
In contrast to secreted mature miRNAs described above,
pre-miRNAs can become biologically active outside the
cell, and therefore may provide some benefit against
ischemic injury.
Several other surprising aspects of miRNA biology also
seem to play a role in stem cell therapy and cardiac
regeneration. For example, cardiomyocyte progenitor
cells can be easily expanded and efficiently differentiated
into beating cardiomyocytes, and alteration of miR-1
and -499 expression levels enhances the cardiomyogenic
differentiation [12]. Additionally, Suzuki et al. [13]
demonstrated that diazoxide, which has been widely
demonstrated to suppress cell apoptosis and promote
cell survival, potentiates mesenchymal stem cell survival
via nuclear factor kappa-B (NF-kB)-dependent miR-146a
expression by targeting Fas. Finally, Kim et al. [14]
demonstrated that ischemic preconditioning (brief,
deliberately induced episodes of ischemia) reduced
apoptosis in mesenchymal stem cells via translocation
of hypoxia-inducible factor-1a (HIF-1a) and the sub-
sequent induction of miR-210 expression. They also
demonstrated that the cytoprotection afforded by
ischemic preconditioning was regulated, in part, by
miR-210-mediated repression of FLICE-associated huge
protein (FLASH)/caspase-8-associated protein-2 (Cas-
p8ap2). Interestingly, their in-vivo studies in a rat
model of acute myocardial infarction demonstrated
that not only did miR-210 play a role in improved
transplanted stem cell survival after engraftment but that
the surrounding heart tissue also expressed higher levels
of miR-210. It is tempting to speculate that the engrafted
mesenchymal stem cells may be able to serve as a source
of miR-210 by shed/secreted phospholipid vesicles for
delivery to the host cardiomyocytes.
Taken together, these studies suggest mesenchymal stem
cells can potentially exert miRNA-mediated biological
effects on cardiomyocytes, endothelial cells, and vascular
smooth muscle cells through the secretion of pre-miRNA
in phospholipid vesicles, which in turn may provide
benefit against ischemic injury. Therefore, the engineer-
ing of mesenchymal stem cells to deliver specific miRNAs
may facilitate the healing process. Furthermore, these
studies suggest that experimental approaches that aug-
ment or attenuate miRNA levels may also be utilized to
enhance cardiomyogenic differentiation and accelerate
stem cell viability of engraftment in the infarcted
myocardium.
miRNA therapeutics
Recent studies have identified miRNA expression signa-
ture patterns that are associated with pathological cardiac
hypertrophy, heart failure, and myocardial infarction in
humans. Therefore, when miRNA attenuation plays a
pathological role in cardiovascular disease, an in-vivo
therapy that leads to increased levels of a specific mature
miRNA, or miRNAs, would be desirable. Thus, to
increase the effective concentration of a depleted
endogenous miRNA and, in turn, more potently block
targeted gene expression, the delivery of a partially
double-stranded stem-looped RNA (pre-miRNA) that
mimics the Dicer cleavage product (i.e., mature, func-
tional miRNA) is required. Remember that the double-
stranded structure is necessary for the appropriate
processing and incorporation into the RISC, after
which the miRNA mimic can function like the endogen-
ous mature miRNA. In a ground-breaking in-vivo study,
Wang et al. [15] demonstrated that infusion of miR-9
mimics reduced isoproterenol-induced cardiac hypertro-
phy and improved cardiac function, in part, through the
regulation of the miR-9 target, myocardin. While this
therapeutic intervention would supplement the mature
miRNA levels that were decreased during disease
progression, it may also result in potential off-target
effects given that the infused mimic would also be taken
up by tissues that do not normally express the miRNA of
interest. It may be possible to circumvent this problem
by delivering miRNA mimics in a cardiac-specific
manner by utilizing serotype-specific adeno-associated
viruses (i.e., AAV9) genetically modified to express a
given miRNA mimic with a cardiac-specific promoter
[16]. While systemic viral delivery of miRNAs to the heart
during disease has yet to be performed, AAV9 has been
successfully utilized to deliver RNA interference to
cardiac tissue and effectively restore cardiac function in
rodents with heart failure [17].
In contrast, when miRNA overexpression plays a
pathogenic role in cardiovascular disease, an in-vivo
therapy that leads to decreased levels of a specific
mature miRNA, or miRNAs, would be desirable. There-
fore, to reduce the effective concentration of an
overexpressed endogenous miRNA and, in turn, increase
targeted gene expression, the delivery of either choles-
terol-conjugated antisense miRNA inhibitors (antago-
mirs) or miRNA sponges (i.e., RNA containing 4–10
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Importantly, the pioneering “proof of concept” studies
for utilizing antagomirs and sponges in a cardiovascular
setting by Carè et al. [18] demonstrated that the in-vivo
inhibition of miR-133 by infusion of an antagomir or a
sponge, delivered inside the cell by adenoviral infection,
caused marked and sustained cardiac hypertrophy in
mice, associated with a re-induction of fetal gene
expression. In support of this first study, Thum et al.
[19] demonstrated that in-vivo silencing of miR-21 by a
specific antagomir in a mouse pressure-overload-
induced disease model reduced cardiac ERK-MAP kinase
(extracellular signal-regulated kinase–mitogen-activated
protein kinase) activity, inhibited interstitial fibrosis,
and attenuated cardiac dysfunction. Taken together,
these studies provide evidence validating the efficacy of
utilizing antagomirs and sponges to silence miRNA
function in vivo.
Conclusions: opportunities and limitations
Breakthroughs in our understanding of heart patho-
physiology that can then be translated to the clinical
setting through the innovation of novel diagnostics
and therapeutics are urgently needed. Recent studies in
humans and mice have discovered profound and
unexpected functions for miRNAs in numerous facets
of cardiac biology, including the control of myocyte
growth, contractility, fibrosis, and angiogenesis. The
apparent importance of miRNAs and the ability to
manipulate them in vivo provides a unique opportu-
nity to exploit miRNAs therapeutically. Furthermore,
miRNA-based diagnostic markers may be superior to
the currently available markers.
That being said, miRNA-based therapeutics also pose a
unique set of challenges from those associated with
classic drugs given that miRNAs have numerous mole-
cular targets, which increases the probability that the
targeting of a miRNA may perturb multiple cellular
functions, some pathological and others beneficial.
Therefore, in advance of therapeutic targeting of specific
miRNAs, a detailed knowledge of their gene targets,
functions, and tissue distribution is required. Given that
miRNA research is still in an early phase, much of this
information is incomplete. For example, the identifica-
tion of authentic miRNA/mRNA targets remains proble-
matic because mammalian miRNAs bind to mRNA with
imperfect complementarity, and currently we only have a
partial understanding of how binding sites are recog-
nized. Thus, some of the bioinformatically predicted
targets turn out to be false while others are entirely
overlooked. Additionally, issues concerning pharmaco-
kinetics, biodistribution, and cell penetration also
represent likely obstacles to miRNA therapeutic
strategies. Finally, novel strategies and techniques must
be developed to deliver miRNA therapeutics in a tissue-
specific manner (i.e., heart and/or vasculature for
treatment of cardiovascular disease). In conclusion, as
our knowledge regarding miRNA/mRNA target recogni-
tion, miRNA function, and miRNA therapeutic delivery
improve, this information may result in a new wave of
medicinal treatments.
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